Prostate cancer
Conditions
Interventions
Apalutamide Group:None
Abiraterone Group:None
Enzalutamide Group:None
Sponsors
The First Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Pathological diagnosis of prostate cancer; 2. Newly diagnosed metastatic hormone-sensitive prostate cancer detected by imaging; 3. Undergo 68Ga-PSMA PET/CT imaging within 30 days before starting novel endocrine therapy; 4. Receiving novel endocrine therapy as first-line systemic therapy; 5. Complete clinical and follow-up data; 6. ECOG performance status <= 2.
Exclusion criteria
Exclusion criteria: 1. Combined with other malignant tumors; 2. Poor image quality of 68Ga-PSMA PET/CT; 3. Have received any anti-cancer treatment; 4. History of allergic reactions to chemotherapy drugs or contrast agents; 5. Severe organ dysfunction, such as heart, lung, liver, or kidney dysfunction; 6. Incomplete clinical pathological data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Deep PSA response at 6 months after novel endocrine therapy;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Radiographic progression-free survival;PSA progression-free survival; | — |
Countries
China
Contacts
Public ContactNing Xu
The First Affiliated Hospital of Fujian Medical University
Outcome results
None listed